Stay up-to-speed on myeloma news that's written in patient-friendly language. Our "New in Myeloma" articles cover treatment option updates, coverage of advancements from major myeloma academic meetings, and more. With a disease that relapses over time, myeloma patients need to be aware of their options, what is coming in the future and where the science is headed in order to make key life-saving decisions.
A new method (BloodFlow) was developed to increase the negative predictive value and showed an unprecedented sensitivity to detect MRD.
A recent study provided strong evidence for intensification of therapy in patients with high-risk myeloma determined by their genetic profile.
A study evaluates responses to the SARS-CoV-2 vaccination among myeloma patients.
The MonumenTAL study shows durable responses with Talquetamab for relapsed/refractory myeloma
An ongoing trial is using a more intense regimen to treat high-risk smoldering myeloma patients.
Immunotherapy research in myeloma is exploding, evidenced by the MagnetisMM family of studies updated at ASH.
New bispecific combinations in clinical trials show promise for relapsed/refractory myeloma
A NEX-T generation BCMA targeted CAR T for multiple myeloma is being studied that includes shorter processing time and better impact..
The MRD2STOP research shows promise for a potential end to maintenance.
Cevostamab shows promising results in heavily pretreated multiple myeloma patients according to a recent presentation at ASH 2022.